A Phase 2 interventional study of Cemiplimab in Cutaneous Squamous Cell Carcinoma, sponsored by Regeneron Pharmaceuticals. Completed at 22 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to evaluate the efficacy of neoadjuvant cemiplimab as measured by Pathologic complete response (pCR) rate per independent central pathology review.
The secondary objectives of the study are:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria
Key Exclusion Criteria
NOTE: Other protocol-defined Inclusion/Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Will receive IV infusion Q3W
Drug: Cemiplimab
Intravenous (IV) infusion every 3 weeks (Q3W)
Also known as: REGN2810, Libtayo
Number of Participants With Pathologic Complete Response (pCR) as Assessed by Independent Central Pathology Review
Time frame: Up to 12 weeks
Number of Participants With Major Pathologic Response (mPR) as Assessed by Independent Central Pathology Review
Time frame: Up to 12 Weeks
Number of Participants With Pathologic Complete Response (pCR) as Assessed by Local Pathology Review
Time frame: Up to 12 weeks
Number of Participants With Major Pathologic Response (mPR) as Assessed by Local Pathology Review
Time frame: Up to 12 Weeks
Percentage of Participants With Objective Response Rate (ORR) Prior to Surgery, According to Investigator Assessment Using RECIST 1.1
Time frame: Up to 12 Weeks
Number of Participants With Planned and Actual Surgery After Neoadjuvant Cemiplimab
Time frame: Up to 12 Weeks
Number of Participants With Planned and Actual Post-Surgical Management
Time frame: Up to 14 Weeks
Event Free Survival (EFS)
Time frame: Up to 50 Months
Disease Free Survival (DFS)
Time frame: Up to 47 Months
Overall Survival (OS)
Time frame: Up to 50 Months
Incidence of Adverse Events (AEs)
Time frame: Up to 52 Months
Incidence of Serious Adverse Events (SAEs)
Time frame: Up to 52 Months
Incidence of Deaths
Time frame: Up to 52 Months
Incidence of Laboratory Abnormalities
Time frame: Up to 52 Months
| Milestone | Cemiplimab 350mg Q3W |
|---|---|
| Started | 79 |
| Completed | 0 |
| Not completed | 79 |
| Withdrew: Study ongoing | 68 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Decision by the investigator | 1 |
| Withdrew: Death | 5 |
| Withdrew: Withdrawal by subject | 4 |
| Participants | Cemiplimab 350mg Q3W |
|---|---|
| Number of Participants With Major Pathologic Response (mPR) as Assessed by Independent Central Pathology Review | 10 |
| Participants | Cemiplimab 350mg Q3W |
|---|---|
| Number of Participants With Pathologic Complete Response (pCR) as Assessed by Independent Central Pathology Review | 40 |
| Participants | Cemiplimab 350mg Q3W |
|---|---|
| Number of Participants With Pathologic Complete Response (pCR) as Assessed by Local Pathology Review | 42 |
| Participants | Cemiplimab 350mg Q3W |
|---|---|
| Number of Participants With Major Pathologic Response (mPR) as Assessed by Local Pathology Review | 10 |
| Percentage of Participants | Cemiplimab 350mg Q3W |
|---|---|
| Percentage of Participants With Objective Response Rate (ORR) Prior to Surgery, According to Investigator Assessment Using RECIST 1.1 | 68.4 (56.9 to 78.4) |
| Participants | Cemiplimab 350mg Q3W |
|---|---|
| Participants with Planned Mohs Surgery | 2 |
| Participants with Actual Mohs Surgery | 2 |
| Participants with Planned Non-Mohs Surgery | 77 |
| Participants with Actual Non-Mohs Surgery | 68 |
| Participants | Cemiplimab 350mg Q3W |
|---|---|
| Planned radiation therapy after surgery | 47 |
| Actual radiation therapy after surgery | 17 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over From first dose to the end of treatment period (Week 25) up to 01-DEC-2021 Data cut-off. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cemiplimab 350 mg Q3W | 6/79 (7.6%) | 15/79 (19%) | 60/79 (75.9%) |
| Event | Cemiplimab 350 mg Q3W |
|---|---|
| Myocardial infarctionCardiac disorders | 2/79 |
| Acute myocardial infarctionCardiac disorders | 1/79 |
| Atrial flutterCardiac disorders | 1/79 |
| Cardiac failure congestiveCardiac disorders | 1/79 |
| CardiomyopathyCardiac disorders | 1/79 |
| ColitisGastrointestinal disorders | 1/79 |
| DysphagiaGastrointestinal disorders | 1/79 |
| CholelithiasisHepatobiliary disorders | 1/79 |
| Immune-mediated hepatitisHepatobiliary disorders | 1/79 |
| COVID-19 pneumoniaInfections and infestations | 1/79 |
| Event | Cemiplimab 350 mg Q3W |
|---|---|
| FatigueGeneral disorders | 24/79 |
| DiarrhoeaGastrointestinal disorders | 12/79 |
| NauseaGastrointestinal disorders | 12/79 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 11/79 |
| ConstipationGastrointestinal disorders | 10/79 |
| PruritusSkin and subcutaneous tissue disorders | 8/79 |
| HypothyroidismEndocrine disorders | 7/79 |
| Decreased appetiteMetabolism and nutrition disorders | 7/79 |
| DizzinessNervous system disorders | 6/79 |
| RashSkin and subcutaneous tissue disorders | 5/79 |
| Age, Continuous(years) | Cemiplimab 350mg Q3W |
|---|---|
| Mean | 71.5 ± 11.3 |
| Age, Customized(Participants) | Cemiplimab 350mg Q3W |
|---|---|
| 17 years and under | 0 |
| 18 to 64 years | 18 |
| 65 to 84 years | 54 |
| 85 years and over | 7 |
| Sex: Female, Male(Participants) | Cemiplimab 350mg Q3W |
|---|---|
| Female | 12 |
| Male | 67 |
| Race/Ethnicity, Customized(Participants) | Cemiplimab 350mg Q3W |
|---|---|
| White | 69 |
| Asian | 1 |
| Other | 1 |
| Unknown / Not Reported | 8 |
| Race/Ethnicity, Customized(Participants) | Cemiplimab 350mg Q3W |
|---|---|
| Not Hispanic or Latino | 74 |
| Unknown/Not Reported | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Ran from Mar 2020 to primary completion in Dec 2021, 20 months.
Results were first posted in Feb 2023, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemiplimab